Home > Medical News > Latest Medical News > The first generic carfilzomib for injection of Hausen Pharmaceuticals was approved for only two months after the original research report

The first generic carfilzomib for injection of Hausen Pharmaceuticals was approved for only two months after the original research report

  • Last Update: 2021-09-11
  • Source: Internet
  • Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

On September 7, CDE's official website showed that Hausen Pharmaceuticals' application for carfilzomib for injection was accepted and accepted

From: CDE official website

Carfilzomib (carfilzomib) is a proteasome inhibitor, approved by the FDA on July 20, 2012, for patients with multiple myeloma who have received at least two previous types (bortezomib and immunomodulators).

The drug's rights have changed hands several times: it was originally developed by Proteolix.

In November 2019, BeiGene and Amgen reached a cooperation to develop and commercialize Amgen's many products in China, one of which is Carfilzomi (KYPROLIS®)

Proteasome inhibitors are the first line of choice for multiple myeloma.

In a phase III study code-named ENDEAVOR, the results of an overall survival (OS) interim analysis according to a predetermined plan showed that Kyprolis (carfilzomib) + dexamethasone treats patients with relapsed or refractory multiple myeloma Compared with Velcade (bortezomib) + dexamethasone, the median OS can be prolonged by 7.

Since its listing, Carfilzomi's sales have continued to grow

Image source: Insight database (https://db.

Insight database shows that at present, no carfilzomib product has been approved for listing in China except for the original research

At present, in addition to Hausen, there are five other companies deploying carfilzomi generic drugs, all of which are currently in the clinical approval stage

Details of competition of carfilzomib for injection

Image source: Insight database (https://db.

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Contact Us

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.